Menten AI
Menten AI, formerly known as Menten Biotechnology Labs, Inc., is a San Francisco-based company specializing in designing protein drugs and enzymes using quantum computing and machine learning for the healthcare industry.
Company History
Menten AI, previously known as 'Menten Biotechnology Labs' and 'Inc.', is located in San Francisco, CA, USA. It participated in the Y-Combinator W20 batch. The company specializes in healthcare, particularly in drug discovery and delivery. Menten AI is known for utilizing quantum computing and machine learning to design protein drugs and enzymes. The company is developing three new proteins, including a peptide to prevent the spread of viruses such as Covid-19.
Services and Technologies
Menten AI designs protein drugs and enzymes using cutting-edge quantum computing and machine learning techniques. It has created the first protein design algorithm for current and near-term quantum computers. The company uses a generative AI platform to design peptide therapeutics, focusing on peptide macrocycles. This platform is validated across the preclinical discovery pipeline, from in silico to in vitro and in vivo efficacy, and it designs peptide macrocycles in a larger chemical space and in record time compared to industry standards.
Partnerships and Collaborations
Menten AI is engaged in two paid pilot projects with multinational chemical companies and holds four letters of intent (LOIs) with other pharmaceutical and biotech companies. It has partnered with Ginkgo Technology Network to enhance R&D using advanced AI for cyclic peptide design. The firm is backed by notable venture capitalists including Uncork Capital, Khosla Ventures, Social Impact Capital, and Y-Combinator.
Employee Benefits
Operating with a team size of two, Menten AI offers comprehensive benefits to its employees. These include full medical coverage, unlimited vacation, wellness and fitness allowances, and a competitive compensation package that includes equity options. The company follows a remote-first work policy, accommodating remote and partly remote work setups.
Expert Contributions and Recognition
Menten AI has made significant contributions to the field of drug discovery. The team co-authored a chapter on quantum computing in Wiley’s book 'Computational Drug Discovery: Methods and Applications.' They were also represented at the APS 2023 conference, where they discussed their advanced generative AI platform for macrocyclic peptide therapeutics.
